Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?

20 Jan 2016

Abstract excerpt

More than 20 years ago, X-linked severe combined immunodeficiency (SCID-X1) appeared to be the best condition to test the feasibility of hematopoietic stem cell gene therapy. The seminal SCID-X1 clinical studies, based on first-generation gammaretroviral vectors, demonstrated good long-term immune reconstitution in most treated patients despite the occurrence of vector-related leukemia in a few of them. This gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to RNA Interference and Gene Delivery
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26790362
DOI: 10.1089/hum.2015.137

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?PMID 26790362Read ↗

Immune Reconstitution After Gene Therapy Approaches in Patients With X-Linked Severe Combined Immunodeficiency DiseaseSemantic proximity Read ↗

Clinical Applications of Gene Therapy for Primary ImmunodeficienciesSemantic proximity Read ↗

Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.Semantic proximity Read ↗

A modified γ-retrovirus vector for X-linked severe combined immunodeficiency.Semantic proximity Read ↗

Gene therapy for severe combined immunodeficiencies and beyondSemantic proximity Read ↗

Gene therapy for PIDs: Progress, pitfalls and prospectsSemantic proximity Read ↗

Gene therapy and genome editing for primary immunodeficiency diseasesSemantic proximity Read ↗

Self-inactivating Gammaretroviral Vectors for Gene Therapy of X-linked Severe Combined ImmunodeficiencySemantic proximity Read ↗

Concise Review: Lessons Learned From Clinical Trials of Gene Therapy in Monogenic Immunodeficiency DiseasesSemantic proximity Read ↗

Preclinical Development of a Lentiviral Vector for Gene Therapy of X-Linked Severe Combined ImmunodeficiencySemantic proximity Read ↗

[Gene therapy of SCID-X1].Semantic proximity Read ↗

Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiencySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.